Paula B Blomquist

Biographic Data

ID10726352
NAMEPaula B Blomquist
GIVEN NAMESPaula B
FAMILY NAMEBlomquist
SIGNATUREBLOMQUIST P B
AFFILIATIONSFrom the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un
VERIFIEDNo
TOTAL WORKS1
TOTAL CITATIONS0
AUTHOR COUNT1
EDITOR COUNT0
FIRST PUBLICATION YEAR2022
LATEST PUBLICATION YEAR2022
H-INDEX0

  • Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

    Nick Andrews, Julia Stowe et al.ARTICLENew England Journal of Medicine2022

    BACKGROUND: A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines. METHODS: We used a test-negative case-control design to estimate vaccine effectiveness against symptomatic disease caused by the omicron and delta (B.1.617.2) variants in England. Vaccine…